NCT06480136View on ClinicalTrials.gov

SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line Treatment

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

June 15, 2027

Study Completion Date

February 15, 2028

Conditions

NSCLC

Interventions

DRUG

SHR-A1921 injection and adebrelimab injection

The Treatment group receive SHR-A1921 injection combined with adebrelimab injection

All Listed Sponsors

lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER